Metoprolol-Induced Lichenoid Dermatitis
نویسندگان
چکیده
منابع مشابه
Lichenoid contact dermatitis secondary to methylisothiazolinone (MI)
MCI: methylchloroisothiazolinone MI: methylisothiazolinone INTRODUCTION Methylisothiazolinone and methylchloroisothiazolinone (MI/MCI) are broad-spectrum preservatives widely used in cosmetics and household and industrial products. It is well known that MI/MCI can cause allergic contact dermatitis with a spongiotic reaction pattern. Because of this reaction, restrictions have been placed on the...
متن کاملLichenoid and granulomatous dermatitis: Report of two cases from Iran
Lichenoid and granulomatous dermatitis is a new entity which is histologically defined by a band like lymphocytic infiltration in the upper portion of the dermis with obscuring the dermoepidermal junction and accompanied by basal layer degeneration and granulomatous inflammation. Herein, we presented two Iranian women with similar cutaneous and histopathologic findings. Both patients had asympt...
متن کاملINH induced lichenoid eruptions.
A 15 year old boy admitted with fever for 10 days associated with altered sensorium. Clinical findings and relevant investigations (including CSF study) were consistent with the diagnosis of tubercular meningitis (TBM). He was put on oral corticosteroid and CAT-.I antitubercular drugs (ATD) (Thrice weekly dosage of INH: 600mg; Rifampicin: 450mg, Ethambutol: 1200mg, Pyrazinamide: 1500mg) [Day 1]...
متن کاملLichenoid dermatitis--treatment with pulsed dye laser: a case study.
BACKGROUND AND OBJECTIVES Both the diagnosis and the treatment of lichenoid dermatosis are often difficult and can be time-consuming. There are now more and more publications about the use of laser systems--especially the flashlamp-pumped pulsed dye laser--in the treatment of inflammatory dermatoses, although the laser's exact mechanism of action in these cases is not yet clear. STUDY DESIGN/...
متن کاملImatinib mesylate-induced lichenoid drug eruption.
Imatinib mesylate (imatinib) is a tyrosine kinase inhibitor initially approved by the US Food and Drug Administration in 2001 for chronic myeloid leukemia (CML). Since then, the number of indicated uses for imatinib has substantially increased. It is increasingly important that dermatologists recognize adverse cutaneous manifestations of imatinib and are aware of their management and outcomes t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of General Internal Medicine
سال: 2011
ISSN: 0884-8734,1525-1497
DOI: 10.1007/s11606-011-1742-5